Interaction Color Code
Clinical Bottom Line
Do not coadminister: Increased levels of izoniazid and reduced levels of dolutegravir
Drug 1
Drug 1 dose
50 mg once daily
Drug 1 effect
AUC decreased 46%, Cmin decreased 74%
Drug 2
Drug 2 dose
15 mg / kg + rifapentine 900 mg once weekly
Drug 2 effect
INH AUC increased 67-92% in 2 / 4 subjects. Rifapentine no significant change.
Clinical Effects
Potential for increased adverse effects of isoniazid (flu-like symptoms, nausea, vomiting, and fever)
Management
Use alternative agents
Import ID
113
